





An improved understanding of the interactions at the nanoscale level between the
bioceramics in medical impl~ntsand th.ehard or soft tissues in the human body could
contribute significantly to the design of new-generation prostheses and postoperative
patient management strategies. Overall, the benefits of advanced ceramic materials in
biomedical applications have been universally accepted, specifically in terms of their
strength, biocompatibility, hydrophilicity, and wear resistance in articulating joints. The
cqntil)uqus development of new-generation implants utilizing nanocoatings with novel
nanosensors and devices is leading to better compatibility with human tissue and
improved well-being and longevity fqr patients. This article gives a short overview of
bloceramlcs and reexamines key issues of concern for processing and applying
nanoceramics as biomaterials.
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Introduction
At present, the most common materials
in clinical use are those chosen from a
handful of well-characterized and available
biocompatible ceramics, metals, polymers,
and their combinations as composites or
hybrids. Advances in the fundamental un-
derstanding of cell and molecular biology,
tissue engineering, targeted drug delivery,
wound healing, and other biomedical
processes, together with the development
of new enabling technologies such as
microscale, nanoscale, and bio-inspired
fabrication (biomimetics) and surface
modification methods, have the potential
to drive at an unprecedented rate the design
and development of new biomaterials use-
ful for medical applications. The current
focus is on the production of new nano-
ceramics relevant to a broad range of
applications such as implantable surface-
modified medical devices for better hard-
and soft-tissue attachment, increased
bioactivity, tissue regeneration and engi-
neering, cancer treatment, drug and gene
delivery, treatment of bacterial and viral
infections, delivery of oxygen to damaged
tissues, imaging, and materials for mini-
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mally invasive surgery. A more futuristic
view includes nanorobotics, nanobiosen-
sors, and micro-nanodevices for a wide
range of biomedical applications.
The opportunity to significantly improve
the clinical usefulness ofbiomaterials, par-
ticularly on the nanoscale, provided by
these advances should be seized by pro-
moting and supporting research and
development of novel new-generation
biomaterials with improved bioactivity
and mechanical properties. Specifically,
these new concepts and strategies for fab-
rication methods and improved tissue in-
teractions could lead to biomaterials that
are truly biocompatible and bioresponsive
at a nanoscale level, similar to biogenic
(natural) materials.
Abiomaterial by definition is a nondrug
substance suitable for inclusion in systems
that augment or replace the function of
bodily tissues or organs. A century ago, ar-
tificial devices made from materials as di-
verse as gold and wood were developed
to a point where they could replace various
components of the human body. These
materials are capable of being in contact
with body fluids and tissues for prolonged
periods of time while eliciting little if any
adverse reaction. 1
The main factors in any biomaterial's
clinical success are its biocompatibility
and biofunctionality, which are directly re-
lated to tissue/implant interface interac-
tions. Improvement of interface bonding
by nanoscale coatings, based on bio-
mimetics, has been of worldwide interest
during the last decade. Currently, a number
of companies are in the commercialization
stages of new-generation nanoscale-
modified implants for orthopedic, ocular,
and maxillofacial surgery and for hard-
and soft-tissue engineering (e.g., Iso'Iis
BV,ApaTech Ltd., £lex Corp.).
The worldwide biomaterials market is
valued at close to $24 billion. Orthopedic
and dental applications represent approxi-
mately 55% of the total biomaterials
market. Sales of orthopedic products
worldwide exceeded $13 billion in 2000,
an increase of 12% over 1999 revenues.'
Expansion in these areas is expected to
continue, due to a number of factors in-
cluding the aging population, an increas-
ing preference by younger to middle-aged
candidates to undergo surgery, improve-
ments in technology, a better understand-
ing of biomechanics, the desire to improve
one's appearance, and the demand by pa-
tients for better performance from ortho-
pedic products.
Biomaterials and Bioceramics
It has been long accepted that no foreign.
material placed within a living body is
completely compatible with it. The only
substances that conform completely are
those manufactured by the body itself
(autogenous); any other substance that is
recognized as foreign initiates some type
of reaction. The question for biomaterials
researchers is, with our ability to control
surfaces at the nanoscale level, and with
the range of new-generation novel "nano-
treatments" being developed, can we
somehow deceive the body into allowing
synthetic materials to be accepted as bio-
genic or autogenic?
When a synthetic material is implanted
in the human body, the tissue reacts in a
variety of ways, depending on the mate-
rial used. The mechanism of tissue inter-
action at the nanoscale depends on the
tissue's response to the implant surface. In
general, three terms describe or classify a
biomaterial with respect to the tissue re-
sponse: bioinert, bioresorbable, and bio-
active.Abioinert material, such as alumina,
is accepted by the body but does not in-
teract or react with the physiological envi-
ronment; a bioresorbable material, such as
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a bioglass, is surface-reactive and dis-
solves within the physiologic environment
to be replaced by the soft or hard tissue;
and a bioactive material, such as hydroxya-
patite, reacts with the tissue and generates
good chemical bonding. These types, each
allowing different means of achieving at-
tachment of implants to the musculo-
skeletal system, are covered in a range of
comprehensive excellent reviews.r"
In the early 1970s, bioceramics were
employed in singular, biologically inert
applications such as bone replacement.
Given that cells and tissues in the body
perform many other vital regulatory and
metabolic functions, the role of bioceramics
has changed from maintaining an essen-
tially physical function, without eliciting a
host response, to providing a more inte-
grated interaction with the host. This has
been accompanied by an increasing
demand on medical devices to improve
the quality of life as well as to extend its
duration.
Bone Replacement Applications
Nanotechnology has opened novel
techniques for the production of bonelike
synthetic nanopowders and coatings of
hydroxyapatite (HAp). Nanoparticles of
HAp [CalQ(p0J6(OHh] have generated
new opportunities in designing superior
biocompatible coatings for implants and
in developing high-strength orthopedic and
dental nanocomposites. Various compa-
nies have synthesized HAp nanoparticles
with diameters in the range of 15-20 nm
and HAp coatings 40 nm thick. Nano-
particles and nanoplatelets of HAp pro-
vide excellent bioactivity arising from the
very high surface area for integration into
bone (Figure 1). Some production tech-
niques and surface modifications (e.g.,
some of the sol-gel techniques, chemical
and vapor deposition techniques, plasma
spray) result in bonds with excellent ad-
Figure 1. Scanning electron microscopy
image of bonelike carbonated apatite
platelets produced at 300°C from a
sol-gel alkoxide system (image by B.
Ben-Nissan, A. Milev, and R. Wuhrer).
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hesive strength between the HAp and the
substrate materials, while others are poor
(electrophoretic deposition, various solu-
tion dip-coating systems, thermal spray).
Currently, a number of companies are pro-
ducing nanocomposites (e.g., Mitsubishi
Materials, ApaTech Ltd., Dentsply Inter-
national, Interpore Cross International,
Wyeth BioPharma, and Medtronic Sofamor
Danek) that incorporate macro- and nano-
particles of HAp and organic and biogenic
materials (e.g., polyethylene, synthetic
peptides and collagen, growth factors).
The combination of macro- and nanopar-
ticles provides mechanical strength not
achievable using nanoparticles alone.
With some of the materials, enhanced
bioactivity and mechanical properties have
been reported in orthopedic and dental
applications such as bone cements and
dental fillings?
The bone mineral is composed of
nanocrystals-or, more accurately, nano-
platelets-originally described as hydroxy-
apatite and similar to the mineral dahllite.
It is now agreed that bone apatite can be
better described as carbonate hydroxy-
apatite (CHA) and approximated by the
formula (Ca,Mg,Na)lo(P04.C03MOHh The
composition of commercial CHA is similar
to bone mineral apatite. Bone pore sizes
range from 1 pm to 100pm in normal cor-
tical bone and from 200 pm to 400 pm in
trabecular bone tissue (found in the ends of
long bones), and the pores are intercon-
nected. Porosity (macroporosity) is intro-
duced in synthetic calcium phosphates
[HAp, tricalcium phosphate (,B-TCP),
CHA] by the addition of volatile com-
pounds such as naphthalene or hydrogen
peroxide.
Bonelike HAp nanopowders and nano-
platelets can be synthesized by a range of
production methods." however, one very
promising method is synthesis from sol-
gel aqueous solutions. Early published
work shows that while biphasic sol-gel
HAp products are easily synthesized,
monophasic HAp powders and coatings
were more difficult to produce. For ex-
ample, synthesis from a stoichiometric
ratio of mixed salt alkoxide sol-gel sys-
tems produces impure HAp accompanied
by a second phase of calcium oxide. Further
investigations into the process showed
that the time period between the mixing
of precursors and heating to remove the
solvent ("aging time") can significantly
alter the composition of the product,"
Orthopedic implants used mainly for
joint replacement and fracture fixation in-
clude metallic (cobalt chromium or tita-
nium alloys) implants, screws, plates, and
nails and their various permutations and
combinations. The most important pa-
rameters for these implants are that they
have the necessary wear resistance, allow
for adequate attachment to bone, and dis-
play the required strength, ductility, and
elasticity? At a bone-implant load-earrying
interface, the greater the implant material
stiffness, the greater load it carries, com-
pared with the surrounding tissue. This
imbalance in load, known as stress shield-
ing, can cause bone tissue to be resorbed.
An implant that is too rigid may also in-
crease the likelihood of bone fracture, as
the bone becomes osteoporotic (thinned)
due to the excessive protection generated
by the stress-shielding effect of the implant.
Implants nanocoated with calcium phos-
phate and possessing the appropriate
bioactivity characteristics, bonding ability,
and design may be the answer to this seri-
ous problem. Oonishi et a1.7 reported in
their experimental and long-term clinical
experience that bioceramics, including
bioinert and bioactive ceramics, are and
will be playing a major role in the
longevity of total joint replacements.
Calcium Phosphate Coatings
It has been accepted that porous HAp
cannot be used for load-bearing applica-
tions due to its unfavorable mechanical
properties. For this reason, HAp has been
used instead as a thin-film coating on
metallic alloys in orthopedic surgery. Of
the metallic alloys used, cobalt chromium
alloys and titanium-based alloys are the
preferred materials for these thin-film
HAp coatings.
Thermal spraying tends to be the most
commonly used coating technique, but in
clinical situations, it is difficult to produce
a controllable resorption response using
implants coated by this method. Problems
arise due to compositional changes in HAp
during spraying at 1600°C and uneven
distribution of the sprayed material, re-
sulting in gaps. Other techniques that are
capable of producing thin coatings in-
clude pulsed laser deposition and sputter-
ing, which, like thermal spraying, involves
high-temperature processing. Other tech-
niques capable of creating nanocoatings,
such as electrodeposition and sol-gel, use
lower temperatures and thus avoid the
problems associated with the structural in-
stability of HAp at elevated temperatures.
The advantages of the sol-gel technique
are numerous; it is nanoscale; it results in
a stoichiometric, homogeneous, and pure
coating due to mixing on the molecular
scale; it allows reduced firing temperatures
due to its small particle sizes with high
surface areas; it has the ability to produce
uniform fine-grained structures; it allows
the use of different chemical routes (alkox-
ide or aqueous-based); and it is easily
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applied to complex shapes with a range of
coating techniques including dip, spin, and
spray coating. Currently, 40 nm. single-
layer pure HAp or carbonated apatites are
easily produced. Multilayered coatings of
up to 12 layers have been reported,"
Developing an understanding of new
materials at the molecular and nanoscale
level has become increasingly critical in
the new era of biomedical materials for
the design and synthesis of nanodevices
on the molecular scale. New technologies,
including molecular self-assembly as a
fabrication tool, will become increasingly
more important in the coming decades.
Basic engineering principles for micro-
fabrication can be leamed through under-
standing the phenomenon of molecular
self-assembly, which is ubiquitous in the
natural world. Coral and bone formation
are good examples of these biomimetic
processes. Coralline apatites can be derived
from sea coral, which is composed of cal-
cium carbonate in the form of aragonite
and is a naturally occurring material that
has optimal strength and structural char-
acteristics. The pore structure of coralline
calcium phosphate produced by certain
species is similar to human cancellous
bone, making it a suitable material for
bone-graft applications. An Australian
coral was converted to monophasic HAp
using a two-stage process in which the
hydrothermal conversion method was
followed by a patented HAp sol-gel
nanocoating? process. This nanocoating
was reported to produce a twofold in-
crease in the biaxial strength of the con-
verted and nanocoated coral, as compared
with the converted-only form. Addition of
bone morphogenic proteins (BMP-2),
growth factors, collagen, and stem cells to
these and similar scaffolding materials is
one of the ongoing research areas in the
nanoceramics field.
Simulated Body Fluid (SBF)
Nanoscale coatings and surface modifi-
cation methods are currently being used
to produce body-interactive materials,
helping the body to heal, and promoting
regeneration of tissues, thus restoring
physiological function. This approach is
being explored in the development of a
new generation of nanobioceramics with a
widened range of applications in maxillo-
facial, orthopedic, and ocular surgery.
Hydroxyapatite layers can be easily
produced on various organic or inorganic
substrates in simulated body fluid (SBF).
SBFhas ionic concentrations of 142.0mM
Na+, 5.0 mM K+, 1.5 mM Mg2+,2.5 mM
Ca2+, 147.8 mM cr. 4.2 mM HC03-,
1.0 mM HPOl-, and 0.5 mM SOl-·
Kokubo'" showed that after immersion in
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SBF(see Figure 2), a wide range of bioma-
terial surfaces display very fine crystallites
of carbonate-ion-eontaining apatite." Bone
cells have been shown to proliferate and
differentiate on this apatite layer, show-
ing increased bioactivity and new bone
formation.
This SBFis highly supersaturated in cal-
cium and phosphate with respect to apatite
under even normal conditions. Therefore,
if a material has an effective functional
group for apatite nucleation on its surface,
it can form the apatite spontaneously. It
has been reported'? that this nucleation
rate can be increased if excessive amounts
of Ca2+ions, PO~21 Si-GH, n-GH, Zr-GH,
Ta-OH, Nb-OH, or similar functional
groups are present. It has been shown"
that highly porous gels of Si021 n021 Zr02I
Nb2051 and Ta20S could form nanocrys-
talline apatite layers on their surfaces in
SBFsolutions.
This method is also being used to meas-
ure the level of bioactivity of an artificial
material by examining apatite-forming
ability on its surface.
Nano- and Macrobioceramics for
Radiotherapy
In drug delivery, the primary aim is to
target drugs to specific sites within the
body. Various nanoceramic drug delivery
systems are currently in clinical evalua-
tion stages. In addition to reducing toxic-
ity to nondiseased cells, the use of these
nanoceramic systems has the potential
benefit of increasing drug efficiency,which
translates to significant cost savings for
many of the expensive drug treatments
now being engineered. Nano drug deliv-
ery systems also have the extraordinary
characteristic of being able to target and
control drug release with very high preci-
sion (see the article by Kriven et al. in this
issue ofMRS Bulletin).
Despite exhibiting excellent preclinical
potentials, several anticancer drugs fail in
their desired clinical activity due to the
lack of specific targeted delivery. Nano-
ceramics are expected to be instrumental
in achieving this targeted delivery.
One of the most common approaches in
cancer treatment is the removal of the dis-
eased parts; unfortunately, recovery or re-
turn of full function is seldom achieved
with this approach. Non-invasive treatment
techniques, in which only the cancer cells
are destroyed, were introduced in mid-
1980s.12Glass microspheres of 17Y203-
19A1203-64Si02 (mol%) composition,
20-30 pm in diameter, were shown to be
effective for targeted radiotherapy of liver
cancer.10.13The 89y in this glass is non-
radioactive, but can be activated by neu-
tron bombardment to 9OY, which is a
,B-emitterwith a half-life of 64.1 h. Current
application involves injection of these
spheres into a diseased liver through the
hepatic artery, where they are entrapped
in small blood vessels, blocking the blood
supply to the cancer and directly irradiat-
ing the cancer with f3 rays. These glass
microspheres are already in clinical use in
Australia, Canada, and the United States.
Oxygen is known to be poorly supplied
to the interior of a tumor because it cannot
penetrate the surrounding layers of can-
cerous cells, and hence a tumor can be de-
stroyed at temperatures of around 43°C,
whereas normal cells can be kept alive
even around 48°C.If ferri- or ferromagnetic
materials are implanted around cancers
and placed under an alternating magnetic
field, it is expected that cancer cells that
are locally heated can be destroyed by the
magnetic hysteresis loss of the ferri- or
ferromagnetic materials. In ceramics, a
critical pore and grain size can be varied
from a few nanometers up to several tens
of nanometers to control the ease of deliv-
ery and dispersion of the materials to the
targeted area. Thus, the characteristic size
of the domain plays a key role in nano-
structured ferromagnetic and ferroelectric
materials. An extremely high magnitude
of magnetic and dielectric permittivity
and the transition in a paramagnetic or
paraelectric state can be observed by de-
creasing grain size down to the nanometer
scale. The use of these nano-sized mate-
rials is currently being investigated for
cancer treatment applications. .
Kokubo and co-workers'<" prepared a
ferrimagnetic glass ceramic containing
36wt% magnetite (Fe304)' 200 nm. in dia-
meter, in a Cao-Si02 matrix. It was reported
that cancerous cells in the medullary (in-
ternal) canal of rabbit tibia were com-
pletely destroyed when this glass ceramic
was inserted into the tibia and placed under
an alternating magnetic field of 300Oe at
100 kHz.J3.l4This kind of invasive treat-
ment, however, cannot be applied to hu-
mans, since cancer cells metastasize. In
human applications, ferri- or ferromag-
netic material must be delivered to the
cancer by injection through blood vessels,
similar to the radioactive microspheres.
For this purpose, the heat-generating effi-
ciency of the ferrimagnetic material must
be further increased. Recently, micro-
spheres 20-30 pm in diameter were formed
by depositing 50 nm. magnetite particles
on silica microspheres 12 pm in diameter,
through the deposition of FeOOH in a so-
lution and its subsequent transformation
into Fe304at 600°Cunder a CO2-H2gas at-
rnosphere." It was reported that its heat-
generating efficiency was about four times
that of the glass ceramic.
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calcium phosphate Formation of apatite
SBF
Figure 2. Schematic representation of the mechanism of apatite formation on NaOH-treated Ti metal in simulated body fluid (SBF) (from
Reference 10).
The synthesis of nanoparticles using the
restricted environments offered by surfac-
tant systems such as water-in-oil micro-
emulsions (reverse micelles) provides
excellent control over particle size, inter-
particle spacing, and particle shape. The
controlled environment of the reverse
micelle also allows sequential synthesis,
which can produce a core/shell structure.
Interest in chemically functionalized nano-
particles has resulted in the fabrication of
corel shell materials consisting of ferromag-
netic nanoparticles with gold coatings.
Other types of confined media, including
microporous and mesoporous host mate-
rials, are used to fabricate particles with
nanometer dimensions. The incorporation
of nanophase magnetic particles into lipo-
somes also promotes the development of
materials with a variety of biomedical
applications.
In a new nano-microemulsion system, it
was shown that lipophilic drugs could be
made soluble in the oil core of the micro-
emulsion, hence preventing hydrolysis of
the drug. For a controlled release of a drug
at 43°C, these microemulsion droplets can
be coated with a polymer such as
poly(lactic-co-glycolic acid). Due to their
nanometer size (in the range of 40-60 nm)
and biodegradable polymeric coating,
these nanoencapsulates are expected to
have a long circulation time within the
body and can be released around a solid
tumor by increasing the temperature to
43°C using a laser device.
Bioengineering Applications
At the micro/nano end of bioengineer-
ing, microtechnology and nanotechnol-
ogy have been, and will increasingly be,
used for the fabrication of biodevices
meant for emerging applications such as
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• planar devices (e.g., biosensor arrays,
DNA chips);
• micro/nano biodevices (e.g., nanoscale
biosensors; large-scale integrated biosen-
sors; dynamic equipment using protein
molecular motors);
• artificial organs or tissues (e.g., neu-
ronal cell networks);
• microfluidic devices and biochips (e.g.,
"lab on a chip");
• biomimetics engineering (e.g., bio-
mimetic systems); and
• guided drug delivery to bio-MEMS (bio-
related microelectromechanical systems).
Many of these "proof-of-concept" de-
vices will be using new nanobioceramics
in small quantities, a procedure similar to
that currently used in the electronics in-
dustry, which still utilizes a range of ad-
vanced ceramics in small quantities to
provide essential electronic properties.
Tissue Engineering
Recently, tissue engineering has been
directed toward taking advantage of the
combined use of. living cells and three-
dimensional ceramic scaffolds to deliver
vital cells to the damaged site in the body.
Feasible and productive strategies have
been aimed at combining a relatively tra-
ditional approach, such as bioceramic im-
plants, with the acquired knowledge in
the fields of cell growth and differentia-
tion of osteogenic cells.
Stem cells have been incorporated into
a range of bioceramics. A stem cell is a
type of cell that has the ability to repro-
duce for a long period of time. It also can
give rise to specialized cells that make up
the tissues and organs of the body. An
adult stem cell is an undifferentiated (un-
specialized) cell that occurs in a differenti-
ated (specialized) tissue, renews itself, and
becomes specialized to yield all of the spe-
cific cell types of the tissue from which it
originated. Cultured bone marrow cells,
derived from adult stem cells, can be re-
garded as mesenchymal precursor cell
populations and are similar to stem cells
in that they also can differentiate into dif-
ferent lineages-osteoblasts, chondrocytes,
adipocytes, and myocytes. When im-
planted into immunodeficient mice, these
cells can combine with mineralized three-
dimensional scaffolds to form highly vas-
cularized bone tissue. These nanoscale
cultured cell/bioceramic composites can
be used to treat full-thickness gaps in long-
bone shafts with excellent integration of
the ceramic scaffold with bone and good
functional recovery (see Figure 3).15Excel-
lent innovative work with these new
nanobioceramics, including biogenic ad-
ditives, is in progress, and clinical applica-
tion is becoming common.P
Concluding Remarks
Nanotechnologies are one of the key ad-
vancements of the 21st century. Rationally
designed materials synthesized by "bottom-
up" approaches can permit the tailoring of
properties from the atomic to the meso-
scopic and macroscopic length scales. This
ability to tailor a material's properties over
broad length scales suggests that research
on hybrids can have a significant impact
on fields as diverse as nanophotonics,
separation techniques, catalysis, smart
coatings, sensors, cosmetics, and biomedi-
cine, as well as ceramic and polymer com-
posite applications.
It is believed that the synthesis of hybrid
organic-inorganic bio-nanocomposites,
biogenic inorganic materials, bioactive inor-
ganic and hybrid materials; the identifica-
tion of their properties; the understanding
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Figure 3. (a)-(c) Bone regeneration therapy using marrow mesenchymal cells for bone graft
applications for increased bioactivity: (a) bone marrow cells from a syringe are combined
with porous hydroxyapatite (HAp, e.g., coralline apatite); (b) the marrow celVHAp composite
is cultured in an osteogenic medium; (c) after 2-3 weeks of culture, the cultured bone graft !HAp
hybrid is inserted into a bone defect. (d)-(f) Application of bone regeneration therapy
method using marrow mesenchymal cells to a macro textured orthopedic hip implant for
increased bioactivity: (d) bone marrow cells are introduced into a joint prosthesis; (e) the
prosthesis is cultured in an osteogenic medium; (f) after 2-3 weeks of culture, the
prosthesis is implanted in a total hip replacement. (From Reference 15.)
of self-assembly and templated growth
processing; and the engineered organization
of solids at organic/inorganic interfaces
will be the precursors of future nanosen-
sors and nanornachines.
Biornimetic and bioinspired approaches
to materials and templated growth of
inorganic or hybrid networks using self-
assembled hybrid organic-inorganic inter-
faceswill also help to extend this promising
domain. Chemically derived hybrid mate-
rials lie at the interface of the organic-
inorganic and biological realms. The main
advantages in the use of these hybrids
result from their high versatility, offering
a wide range of possibilities to produce
elaborate tailor-made materials in terms of
chemical and physical properties. Moreover,
these hybrid nanocomposites present the
paramount advantage of facilitating inte-
gration, miniaturization, and multifunc-
tionalization of the devices, opening a
new range of opportunities for many
applications.
In nature, many structures are pro-
duced by biornimetic processes. These are
usually fine hybrid structures, and are
hardly reproducible by current classical
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consolidation processes. However, it can
be easily predicted that in due time, more
and more inorganic/organic/biological
hybrid materials incorporating bone mor-
phogenic proteins and stem cells will be
introduced, opening completely new per-
spectives in biomaterials production and
application methods.
The current development of new novel
nanocerarnics is encouraging, and they
can be used for a broad spectrum of
medical applications such as implantable
medical devices, tissue engineering, drug
and gene delivery, imaging agents, mate-
rials for minimally invasive surgery, and
biosensors. Biocerarnics-and specifically,
nanobiocerarnics-are fundamental to the
design and development of a wide variety
of medical devices and implants.
The scope for the application of
nanoscale technologies to medical appli-
cations may cover the surgical, basic
science, and engineering aspects ofbiorna-
terials and the relevant design and produc-
tion characteristics of devices constructed
from these biomaterials, as well as their
clinical performance. Collaborative inter-
disciplinary research involving surgeons,
materials scientists, biologists, physiolo-
gists, clinicians, engineers, and experts in
any of the quantitative sciences is perti-
nent for the success of this exciting and
promising field.
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